Quantification approaches of positron emission tomography (PET) imaging provide user-
independent evaluation of pathophysiological processes in living brains, which have been …

Purpose The research community has focused on defining reliable biomarkers for the early
detection of the pathological hallmarks of Alzheimer's disease (AD). In 2017, the Geneva AD …

Background Using multiple modalities of biomarkers, several machine leaning-based
approaches have been proposed to characterize patterns of structural, functional and …

Objectives Quantification of tau accumulation using positron emission tomography (PET) is
critical for the diagnosis of Alzheimer's disease (AD). This study aimed to evaluate the …

The significance of data analytics and machine learning has increased in managing vast
quantities of healthcare data effectively. According to recent statistics, Alzheimer's disease is …

Purpose A unique advantage of the brain positron emission tomography (PET) imaging is
the ability to image different biological processes with different radiotracers. However, the …

Background Patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) have
high variability in brain tissue loss, making it difficult to use a disease-specific standard brain …

Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects
cognitive functions such as memory, thinking, and behavior. In this disease, there is a critical …

The emergence of tau PET imaging over the last decade has enabled Alzheimer's disease
(AD) researchers to examine tau pathology in vivo and more effectively characterize the …

Purpose Quantification of tau load using 11 C-PBB3-PET has the potential to improve
diagnosis of neurodegenerative diseases. Although MRI-based pre-processing is used as a …